List of Excipients in Branded Drug TURALIO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Daiichi Sankyo Inc	TURALIO	pexidartinib	65597-402	CROSPOVIDONE	2036-05-05
Daiichi Sankyo Inc	TURALIO	pexidartinib	65597-402	FERRIC OXIDE YELLOW	2036-05-05
Daiichi Sankyo Inc	TURALIO	pexidartinib	65597-402	FERROSOFERRIC OXIDE	2036-05-05
Daiichi Sankyo Inc	TURALIO	pexidartinib	65597-402	HYPROMELLOSE	2036-05-05
Daiichi Sankyo Inc	TURALIO	pexidartinib	65597-402	MAGNESIUM STEARATE	2036-05-05

TURALIO (Pexidartinib) Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

TURALIO is a 125 mg pexidartinib capsule approved for adults with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not adequately managed by surgery. Its commercial opportunity is concentrated in formulation differentiation, adherence, hepatic-risk management, low-fat dosing compatibility, and global lifecycle extensions rather than conventional generic substitution. The key excipient opportunities are lactose reduction or removal, improved capsule usability, modified-release development, and delivery systems that preserve exposure while reducing peak-related tolerability concerns.

What is TURALIO and how is it formulated?

TURALIO contains pexidartinib, a small-molecule inhibitor of CSF1R, KIT, and FLT3. Daiichi Sankyo markets the product in hard gelatin capsules containing 125 mg pexidartinib hydrochloride.

The FDA-approved formulation uses conventional solid oral excipients:

Formulation element	Function
Lactose monohydrate	Diluent and capsule-fill bulking agent
Crospovidone	Superdisintegrant
Sodium lauryl sulfate	Wetting and dissolution aid
Colloidal silicon dioxide	Glidant and flow modifier
Magnesium stearate	Lubricant
Gelatin capsule shell	Dosage-form containment
Titanium dioxide and iron oxides	Capsule colorants
Printing ink	Product identification

The excipient profile is technically conventional, but the product has a demanding clinical-use environment. TURALIO is subject to a boxed warning for serious and potentially fatal hepatotoxicity. The FDA also requires a Risk Evaluation and Mitigation Strategy, or REMS, with liver-function monitoring and controlled distribution requirements.[1]

The formulation therefore has to support more than dissolution. It must provide reproducible exposure across meals, maintain capsule integrity, support a four-capsule daily regimen at the approved dose, and avoid excipient changes that complicate hepatic safety interpretation.

What excipient strategy does TURALIO require?

The strongest strategy is incremental reformulation that improves administration without changing the therapeutic positioning of pexidartinib.

Lactose-free or lactose-reduced capsule

Lactose monohydrate is a standard pharmaceutical diluent, but its presence creates avoidable commercial friction for patients with lactose intolerance, dairy-avoidance preferences, or excipient sensitivity. A lactose-free version could replace lactose with one or more of the following:

• Microcrystalline cellulose
• Mannitol
• Dibasic calcium phosphate
• Pregelatinized starch
• Spray-dried mannitol-cellulose systems

Mannitol is commercially attractive because it has strong patient familiarity, favorable powder handling, and a neutral taste profile. Microcrystalline cellulose can improve capsule-fill robustness but may alter bulk density and disintegration. Calcium phosphate can support compact, high-density fills but requires tighter control of particle-size distribution and lubricant level.

A lactose-free reformulation would be commercially useful, but it would not automatically receive market exclusivity. The value would depend on whether the reformulation delivers a clinically meaningful usability advantage, a patentable composition, or a new dosage form.

Sodium lauryl sulfate optimization

Sodium lauryl sulfate improves wetting and can reduce dissolution variability in hydrophobic drug substances. It can also create formulation and perception issues:

• Potential gastrointestinal irritation
• Sensitivity among excipient-conscious patients
• Dependence on concentration for dissolution performance
• Possible interaction with capsule-shell or packaging systems

Replacing sodium lauryl sulfate with poloxamer 188, sodium stearyl fumarate, surfactant-free micronization, or a lipid-based dispersion could support a differentiated formulation. The commercial case is strongest if the substitute reduces dissolution variability under low-fat meal conditions while retaining the approved exposure profile.

A surfactant-free system would have the clearest positioning for excipient-sensitive patients, but it may require particle engineering, amorphous solid dispersion technology, or wetting-agent substitution. Those changes introduce manufacturing and stability risks.

Capsule-shell reformulation

The current hard gelatin capsule creates several lifecycle opportunities:

• Hypromellose capsule conversion
• Improved moisture-barrier performance
• Vegetarian capsule positioning
• Colorant reduction
• Enhanced printing and product differentiation
• Child-resistant packaging integration

A hypromellose shell could support markets where vegetarian dosage forms are commercially important. It may also improve moisture performance in certain packaging configurations. The change would require comparative stability, dissolution, shell compatibility, and bioequivalence work.

Capsule-shell changes are typically easier to develop than a new active formulation, but they can be difficult to patent broadly. Commercial value may come from market access, procurement preferences, and patient acceptance rather than exclusivity alone.

What formulation patents could protect a TURALIO lifecycle product?

A commercially meaningful TURALIO reformulation would need protection beyond a generic excipient substitution.

Potential patent categories include:

Patent category	Potential claim focus	Commercial value
Composition patent	Pexidartinib with a defined excipient system	High if the composition improves exposure or stability
Particle-engineering patent	Specific particle size, morphology, or crystallinity	High where dissolution is difficult to replicate
Amorphous dispersion patent	Pexidartinib with polymeric carrier	High, but stability must be demonstrated
Food-effect patent	Formulation that reduces exposure variation with meals	High clinical and commercial value
Modified-release patent	Extended or delayed release of pexidartinib	High if peak exposure or adherence improves
Capsule-shell patent	Pexidartinib fill with a defined shell and moisture system	Moderate
Manufacturing patent	Wet granulation, dry granulation, coating, or encapsulation process	Moderate to high as a manufacturing barrier
Method-of-use patent	Use in defined TGCT populations or dosing regimens	High if legally valid and clinically differentiated

The most defensible formulation claims would link the excipient system to a measurable technical result, such as reduced food effect, improved dissolution at a specified pH, reduced degradation, improved capsule stability, or reduced pharmacokinetic variability.

A patent claiming only "pexidartinib plus lactose substitute" would face narrower protection and potential obviousness challenges. A stronger claim would define the active pharmaceutical ingredient, particle properties, excipient ratios, dissolution profile, and pharmacokinetic performance.

When does TURALIO lose exclusivity?

TURALIO has small-molecule generic risk rather than biosimilar risk. Pexidartinib is not a biologic, so the relevant pathway is an abbreviated new drug application, or ANDA, under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The practical exclusivity profile includes:

Protection type	Relevance to TURALIO
New chemical entity exclusivity	Applied at initial FDA approval if eligibility requirements were met
Orphan-drug exclusivity	Relevant because TGCT is a rare disease indication
Orange Book patents	Can delay ANDA approval or trigger Paragraph IV litigation
Method-of-use patents	May limit label use, but do not necessarily block all generic approval
Formulation patents	Could restrict a generic using the protected formulation
REMS requirements	May create operational barriers but do not independently create long-term exclusivity
Pediatric exclusivity	Applies only if FDA requirements were completed and granted

FDA approved TURALIO on August 2, 2019, under the accelerated approval pathway.[1] Orphan-drug exclusivity can protect the approved indication for seven years from approval, subject to statutory exceptions. The practical generic-entry date depends on the earliest enforceable patent expiration, any six-month pediatric extension, the status of listed use codes, and Paragraph IV litigation outcomes.

The relevant business conclusion is that pexidartinib generic entry is more likely to be constrained by patent and clinical-monitoring complexity than by manufacturing difficulty alone. A generic developer must reproduce exposure, meet capsule quality requirements, address hepatotoxicity-related labeling, and operate within any applicable REMS or restricted-distribution conditions.

What is the Orange Book status of TURALIO?

The Orange Book is the controlling source for current listed patents, use codes, exclusivity periods, and therapeutic-equivalence information. TURALIO should be assessed through the FDA product listing for pexidartinib and the current Orange Book patent-and-exclusivity data rather than through secondary patent databases.[2]

The key legal questions are:

1. Which active-ingredient, formulation, and method-of-use patents are listed?
2. Which claims correspond to the approved TGCT indication?
3. Do listed method-of-use patents cover all clinically relevant uses or only a narrow patient population?
4. Has any ANDA applicant filed a Paragraph IV certification?
5. Has Daiichi Sankyo initiated litigation within the statutory 45-day period?
6. Has a settlement created a licensed or delayed generic-entry date?

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. A timely infringement action would generally impose a 30-month stay on FDA approval, subject to statutory exceptions and court action.

No biosimilar litigation pathway applies. A pexidartinib challenger would pursue an ANDA, not a biosimilar application under section 351(k).

Which companies could challenge TURALIO?

The likely challengers are generic companies with oncology portfolios, controlled-distribution capabilities, and experience with complex oral products. Potential participants include large generic manufacturers and specialty-generic companies, but an actual Paragraph IV challenger must be confirmed through FDA records and federal court filings.

The most likely challenger profiles are:

• Large manufacturers with established oncology ANDA operations
• Companies with capsule manufacturing and analytical-development capacity
• Specialty-generic developers focused on orphan or hospital-administered products
• Contract development and manufacturing organizations partnering with generic applicants
• Regional manufacturers targeting markets where patent protection expires earlier or differs

The principal entry barrier is not active-ingredient synthesis. Pexidartinib is a conventional small molecule. The harder elements are bioequivalence, food-effect control, hepatotoxicity labeling, restricted distribution, and commercial scale in a rare disease.

What commercial opportunities exist for TURALIO excipients?

The highest-value opportunities are listed below.

Opportunity	Product concept	Commercial rationale
Lactose-free TURALIO	Mannitol or cellulose-based capsule fill	Broadens patient acceptability
Low-food-effect TURALIO	Formulation with reduced meal sensitivity	Simplifies administration
Once-daily optimized capsule	Higher-strength or modified-release dosage form	Reduces pill burden
Sprinkle formulation	Capsule contents suitable for administration with soft food	Supports swallowing-challenged patients
Hypromellose capsule	Vegetarian and moisture-optimized shell	Improves global positioning
Pediatric or adolescent formulation	Mini-tablet, granule, or oral suspension	Extends use into younger populations if clinically justified
Adherence packaging	Calendar blister with liver-monitoring reminders	Supports REMS and persistence
Stability-enhanced product	Desiccant-integrated or high-barrier packaging	Improves distribution in hot and humid markets
Generic excipient platform	Replicable pexidartinib capsule technology	Reduces development risk for ANDA sponsors

The most attractive near-term opportunity is a lactose-free, low-food-effect capsule that preserves the existing dose and administration route. It would require less clinical disruption than a modified-release product and could be positioned for international markets where excipient preferences differ.

A sprinkle formulation may have substantial patient value, but pexidartinib’s hepatotoxicity monitoring and specialized indication make pediatric expansion uncertain. The product would require careful control of dose uniformity, taste masking, handling exposure, and food compatibility.

How does TURALIO compare with competing TGCT treatments?

TURALIO has a differentiated position because it is an oral systemic therapy approved specifically for patients with TGCT who have substantial morbidity or functional limitation and are not adequately managed by surgery.[1]

Product or approach	Modality	Excipient opportunity	Competitive issue
TURALIO	Oral pexidartinib capsule	Lactose-free, low-food-effect, modified release	Hepatic monitoring and REMS
Surgery	Procedural treatment	Not applicable	Recurrence and anatomical limitations
Local or systemic investigational therapies	Varies	Depends on modality	Clinical and regulatory uncertainty
Off-label kinase inhibitors	Oral small molecules	Existing generic platforms	Less specific regulatory positioning
Future CSF1R-directed products	Oral or biologic	Potential delivery differentiation	May compete on safety or convenience

TURALIO’s excipient strategy must therefore address the product’s main commercial liabilities: monitoring burden, capsule count, food instructions, and concerns about long-term tolerability. An excipient change that does not improve one of those variables is unlikely to create substantial market value.

What manufacturing and intellectual-property barriers affect TURALIO?

The active ingredient is a small molecule, but commercial replication still requires a controlled manufacturing process. Relevant barriers include:

• Pexidartinib particle-size and polymorph control
• Uniform distribution of low-dose active in the capsule fill
• Surfactant-dependent wetting and dissolution
• Capsule-shell moisture compatibility
• Stability under high-temperature and high-humidity conditions
• Analytical methods for related substances and degradation products
• Food-effect reproducibility
• Packaging that protects the finished capsules
• Compliance with REMS-related distribution controls

A formulation developer should prioritize a design-of-experiments program covering particle size, lubricant concentration, disintegration, surfactant level, capsule-fill weight, and dissolution across physiologically relevant pH conditions.

The strongest IP position would combine formulation claims with process claims. Process claims can reduce the risk that a competitor reproduces the product through a different excipient system. They are less likely to prevent all generic entry than broad composition claims, but they can increase manufacturing complexity and support trade-secret protection.

What is the generic launch risk for TURALIO?

Generic launch risk is moderate rather than immediate or automatic. The product is vulnerable to ANDA competition because it is a small-molecule capsule, but the market is narrow and the safety-management requirements are demanding.

Risk factor	Effect on generic entry
Small-molecule capsule	Favors generic development
Rare TGCT population	Limits expected commercial return
Hepatotoxicity boxed warning	Raises labeling and pharmacovigilance burden
REMS or controlled distribution	Raises operational complexity
Food-effect requirements	Increases bioequivalence risk
Listed patents	Can delay approval or launch
Limited prescriber base	Reduces launch scale
Potential orphan market	Supports premium pricing but limits volume

A first generic could launch through a licensed settlement, at-risk entry after litigation, or approval following patent expiry. The commercial opportunity is strongest for a manufacturer able to supply multiple markets, maintain reliable specialty-pharmacy distribution, and offer a price reduction without creating supply interruptions.

What licensing opportunities exist around TURALIO?

Licensing opportunities are more likely to involve formulation technology than the core pexidartinib molecule. Relevant deal structures include:

• Out-licensing a lactose-free or low-food-effect formulation
• Licensing a modified-release platform to Daiichi Sankyo
• Regional rights for a hypromellose-capsule version
• Co-development of a pediatric or swallow-friendly dosage form
• Supply agreements for specialized capsule shells
• Technology licensing to generic manufacturers after core patent expiry
• Packaging and adherence partnerships tied to REMS operations

A formulation licensor would need to demonstrate a measurable advantage in pharmacokinetics, stability, patient usability, manufacturing cost, or geographic market access. A purely cosmetic excipient change would have limited negotiating value.

Key Takeaways

• TURALIO is a 125 mg pexidartinib hard gelatin capsule for adults with clinically significant TGCT.
• The current formulation uses conventional excipients, including lactose monohydrate, crospovidone, sodium lauryl sulfate, colloidal silicon dioxide, and magnesium stearate.
• The strongest reformulation opportunity is a lactose-free capsule with reduced food-effect variability.
• Hypromellose shells, modified release, sprinkle delivery, and adherence packaging are secondary lifecycle options.
• TURALIO faces generic rather than biosimilar risk.
• Orange Book patents, method-of-use claims, orphan exclusivity, and Paragraph IV litigation determine the practical entry timeline.
• REMS, liver monitoring, food-effect requirements, and the small TGCT market make generic commercialization more complex than ordinary capsule replication.
• The highest-value excipient IP should link composition claims to measurable improvements in dissolution, exposure, stability, or administration.

FAQs About TURALIO Excipient and Commercial Strategy

Does TURALIO contain lactose?

Yes. The approved capsule formulation contains lactose monohydrate as a diluent. A lactose-free version would require a new formulation and comparative regulatory review.

Can TURALIO be reformulated as a tablet?

Yes, technically. A tablet would require redevelopment of powder flow, compaction, dissolution, stability, packaging, and bioequivalence. The commercial case would depend on reducing pill burden or improving administration.

Is pexidartinib suitable for an oral suspension?

Pexidartinib could theoretically be developed as an oral suspension or granule product, but the formulation would require control of dose uniformity, taste, chemical stability, particle settling, preservative performance, and food compatibility.

Could excipients reduce TURALIO liver toxicity?

Excipients cannot be assumed to reduce pexidartinib’s intrinsic hepatotoxicity. A formulation could alter exposure or peak concentration, but any safety claim would require dedicated pharmacokinetic and clinical evidence.

Would a lactose-free TURALIO product receive new patent protection?

It could, but a patent would require novelty and non-obviousness. A broad claim covering a routine lactose replacement would face substantial validity risk. Protection would be stronger if the formulation produced an unexpected dissolution, stability, food-effect, or pharmacokinetic result.

References

1. U.S. Food and Drug Administration. (2019). TURALIO (pexidartinib) prescribing information. Daiichi Sankyo, Inc.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2019). FDA approves first therapy for rare joint tumor. https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-rare-joint-tumor

4. U.S. Food and Drug Administration. (2020). TURALIO Risk Evaluation and Mitigation Strategy. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211810s001lbl.pdf